Immune checkpoint blockers in pts with solid organ transplant and solid tumors. Potential treatm for some pts but limited activity for pts with SOT and 🫁cancer.1/3 have organ rejection within 2mo after treatment initiation.Thanks all authors! OncoAlert
authors.elsevier.com/sd/article/S20…

Natalie Vokes João Alessi, MD Xinan Wang Mark Awad Lynette Sholl Roberto Ferrara Giuseppe Lamberti Alessandro Di Federico, MD

A piece of knowledge about TMB in cancer immunotherapy.
Thanks Biagio Ricciuti, MD PhD for coordinating this

#ELCC24 poster addressing the role of pCR as predictor of EFS benefit for immunotp in early NSCLC, and comparing periop and neoad according to PD-L1 and pCR. Kudos to Antonio Nuccio presenting our work!

ICHNO2024, reporting the results of LEA study on longitudinal performance of plasma EBV-DNA in non-endemic EBV+ nasopharyngeal cancer patients! Thanks to all of the - outstanding and very welcoming at same time - representatives of head and neck oncology!

Great news from Prague ESMO - Eur. Oncology #ELCC24 ! Our work led by Roberto Ferrara on waning effect of EGFR TKIs in adjuvant setting won best poster award! Mario Occhipinti Martina Imbimbo Vittorio Simeon

Best post award for waning effect of adjuvant EGFR TKIs in resected NSCLC. Cochrane Metanalysis Lung Cancer Group. The Cochrane Library Cochrane Mario Occhipinti Martina Imbimbo Vittorio Simeon giuseppe viscardi
#ELCC24

Lung cancer group IRCCS San Raffaele at #ELCC24 ESMO - Eur. Oncology
Ospedale San Raffaele.
Antonio Nuccio his first merit award for poster on perioperative chemo+ICI in NSCLC
Ludovica

Pacific 2 vs 1 from biological perspective:
Does sequential/concurrent RT on lymphonodes negatively impact on priming and proliferation of T-cells under ICI?
A factor to be considered also in oligometastatic setting when RT is given to lymphonodes after systemic ICI? #ELLC24

Food for thoughts on treatment strategies in EGFR-m NSCLC. Questions to me:
-MET IHC is frequently high also in EGFR-TKIs naive setting?
-role of EGFR IHC overexpression (no exact overlap with EGFR-m) for amivantamab+CT as for cetuximab+CT in FLEX trial (jto.org/article/S1556-…)

First mechanistic link between chronic stress and cancer.
Chronic stress anticipates neutrophils diurnal peak in the blood of 5-8 hours.
A factor to be considered in chronoimmunotherapy studies. Stress induced corticosteroids promote metastases growth by inducing NET. Mikala Egeblad

pieces of knowledge about immunotherapy in early NSCLC Roberto Ferrara Antonio Nuccio Marina Garassino valter torri

a meta-analysis exploring the role of clinicopathological variables ejcancer.com/article/S0959-…

MPR and pCR as surrogate endpoints for EFS jto.org/article/S1556-…

It' s not all about pCR. MPR showed good surrogacy score with 2 years EFS (same as pCR) giuseppe viscardi Antonio Nuccio.
Great work led by Valter Torri and Marina Garassino Tina Cascone
JTO & JTO CRR

Highlander (lifespan >5 days) neutrophils trascriptionally adapt to survive in very hypoxic tumor niches and are responsible of accelerated tumor growth in tumor models (and poor prognosis in cancer patients)
doi.org/10.1126/scienc…

🚨Out in Journal of Clinical Oncology our work dissecting the genomic & immunophenotypic correlates of acquired resistance (AR) to PD-(L)1 blockade in #NSCLC . OncoAlert #LCSM Dana-Farber News ASCO IASLC Link: shorturl.at/qyIJ4
1/9

Here you can find everything you need to know when you approach #PrecisionOncology .

Simple & accessible format with tips from incredible experts in the field (thanks to all co-authors!)

Thanks to CA: A Cancer Journal for Clinicians for the opportunity to disseminate our guidance.

Enjoy it!🙂

November issue—
Neoadjuvant Durvalumab Alone or Combined with Novel #ImmunoOncology Agents in Resectable #LungCancer : The Phase 2 NeoCOAST Platform Trial, by Tina Cascone, Patrick Forde et al.
bit.ly/3RmZNIh
MD Anderson Cancer Center Bloomberg~Kimmel Institute @HopkinsKimmel #Immunotherapy